--- title: "GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of \"Hold\" from Brokerages" type: "News" locale: "en" url: "https://longbridge.com/en/news/295890730.md" description: "GoodRx Holdings (NASDAQ: GDRX) has received an average 'Hold' rating from 13 analysts, with a consensus target price of $4.14. Recent reports include Goldman Sachs maintaining a neutral stance at $4.00, while TD Cowen and Citigroup upgraded to 'Buy' with $5.00 targets. Institutional ownership stands at 63.77%, with significant position increases by Essential Partners LLC. The company recently reported Q2 EPS of $0.08, meeting estimates, with revenue of $200.41 million." datetime: "2026-08-14T06:29:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295890730.md) - [en](https://longbridge.com/en/news/295890730.md) - [zh-HK](https://longbridge.com/zh-HK/news/295890730.md) --- # GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have received an average recommendation of "Hold" from the thirteen ratings firms that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.1364. - Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? GDRX has been the subject of several research reports. The Goldman Sachs Group restated a "neutral" rating and set a $4.00 price objective on shares of GoodRx in a research report on Friday, August 7th. Leerink Partners set a $5.00 target price on GoodRx in a report on Thursday, August 6th. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research report on Friday, August 7th. TD Cowen boosted their price target on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Citigroup upped their price objective on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday. **Read Our Latest Analysis on GDRX** ## Institutional Trading of GoodRx - This healthcare stock making a buzz with 160% growth Several hedge funds and other institutional investors have recently bought and sold shares of the company. Essential Partners LLC grew its position in shares of GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after purchasing an additional 11,295 shares during the period. Meridian Wealth Management LLC purchased a new position in GoodRx during the fourth quarter worth about $29,000. SG Americas Securities LLC acquired a new stake in shares of GoodRx in the first quarter worth approximately $29,000. Krilogy Financial LLC acquired a new position in shares of GoodRx in the 1st quarter valued at $33,000. Finally, Quarry LP acquired a new position in GoodRx in the third quarter valued at $33,000. 63.77% of the stock is owned by hedge funds and other institutional investors. ## GoodRx Stock Performance NASDAQ:GDRX opened at $3.72 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average price of $3.01 and a two-hundred day moving average price of $2.58. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a market capitalization of $1.27 billion, a P/E ratio of 93.02, a price-to-earnings-growth ratio of 1.70 and a beta of 1.60. - Gene therapy: Why does it cost millions for a single treatment? GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.08. The company had revenue of $200.41 million during the quarter, compared to analysts' expectations of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The firm's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.09 earnings per share. As a group, research analysts expect that GoodRx will post 0.16 earnings per share for the current fiscal year. ## GoodRx Company Profile (Get Free Report) GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications. In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs. ## Featured Stories - Five stocks we like better than GoodRx - Asian Market Circuit Breakers Hit Stocks, Not AI Demand - Riot Platforms Re-Wires the Ledger for a $9B AI Power Play - Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy? - Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in GoodRx Right Now? Before you consider GoodRx, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list. While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [GDRX.US](https://longbridge.com/en/quote/GDRX.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [RIOT.US](https://longbridge.com/en/quote/RIOT.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [JOBY.US](https://longbridge.com/en/quote/JOBY.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [JOBY+.US](https://longbridge.com/en/quote/JOBY+.US.md) ## Related News & Research - [GDRX: Revenue declines as Pharma Direct and subscriptions grow, but legal and market risks remain high](https://longbridge.com/en/news/295009416.md) - [GoodRx files Form 3 for CFO, Chief Strategy & Operations Officer Justin Fengler](https://longbridge.com/en/news/295712299.md) - [GoodRx names Chief Strategy and Operations Officer Justin Fengler as CFO, succeeding Christopher McGinnis](https://longbridge.com/en/news/295017284.md) - [FocalTherics (NASDAQ:FOCL) Receives Average Rating of "Hold" from Brokerages](https://longbridge.com/en/news/295946793.md) - [Annex Advisory Services LLC Acquires 78,424 Shares of Texas Pacific Land Corporation $TPL](https://longbridge.com/en/news/295631004.md)